Aldeyra Therapeutics has reported that its new experimental drug reproxalap met the primary goal of ocular redness in a Phase II clinical trial in individuals with dry eye disease, a common inflammatory ailment.

The double-masked, randomised, vehicle-controlled Phase II trial recruited 158 subjects, of which 80 were given a 0.25% ophthalmic solution of reproxalap while 78 subjects received vehicle ophthalmic solution.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Findings from the trial showed that ocular redness scores in the reproxalap arm were statistically less than those receiving a vehicle.

Following the first dose, Schirmer’s test results favoured reproxalap as against vehicle and neared statistical significance.

At all 18 time points of symptom evaluation in the dry eye chamber, subjects in the reproxalap group had reduced mean visual analogue scale ocular dryness and ocular discomfort scores versus those in vehicle arm.

The company noted that these differences were not statistically significant.

No safety or tolerability concerns were reported in the trial, which is in line with the clinical data of reproxalap in more than 1,300 subjects.

Mild and temporary instillation site discomfort that lasted for less than a minute was the most common side effect, which is similar to several prescribed topical ophthalmic treatments for anterior segment inflammation.

Aldeyra Therapeutics president and CEO Todd Brady said: “Complementing our rapid and durable symptom control evidenced in three 12-week clinical trials, we are excited to announce the achievement of statistical significance of an objective sign of dry eye disease in a well-controlled clinical trial.

“Ocular redness may be the only dry eye disease sign that is of importance to patients, and the reduction in redness observed in this trial following reproxalap treatment potentially represents a major advance for the chronic treatment of dry eye disease.”

Reproxalap is also currently being analysed in TRANQUILITY and TRANQUILITY-2 Phase III trials in dry eye disease patients.

Both the trials each intend to enrol 300 subjects, with ocular redness being the primary goal.